BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 23672526)

  • 1. Assessing the relationship of paraoxonase-1 Q192R polymorphisms and the severity of lung disease in SM-exposed patients.
    Golmanesh L; Bahrami F; Pourali F; Vahedi E; Wahhabaghai H; Mehrani H; Ghanei M
    Immunopharmacol Immunotoxicol; 2013 Jun; 35(3):419-25. PubMed ID: 23672526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of paraoxonase 1 activity and gene polymorphisms on long-term pulmonary complications of sulfur mustard-exposed veterans.
    Taravati A; Ardestani SK; Ziaee AA; Ghorbani A; Soroush MR; Faghihzadeh S; Kazemi H; Rezaei A; Hoseini H; Ghazanfari T
    Int Immunopharmacol; 2013 Nov; 17(3):974-9. PubMed ID: 23370296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paraoxonase 1 (PON1) 55 polymorphism, lipid profiles and psoriasis.
    Asefi M; Vaisi-Raygani A; Bahrehmand F; Kiani A; Rahimi Z; Nomani H; Ebrahimi A; Tavilani H; Pourmotabbed T
    Br J Dermatol; 2012 Dec; 167(6):1279-86. PubMed ID: 22835076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum albumin and paraoxonase activity in Iranian veterans 20 years after sulfur mustard exposure.
    Taravati A; Ardestani SK; Soroush MR; Faghihzadeh S; Ghazanfari T; Jalilvand F; Naghizadeh MM; Fallahi F
    Immunopharmacol Immunotoxicol; 2012 Aug; 34(4):706-13. PubMed ID: 22208333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum paraoxonase-1 (PON1) activities (PONase/AREase) and polymorphisms in patients with type 2 diabetes mellitus in a North-West Indian population.
    Gupta N; Binukumar BK; Singh S; Sunkaria A; Kandimalla R; Bhansali A; Gill KD
    Gene; 2011 Nov; 487(1):88-95. PubMed ID: 21803130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic effects of BuChE non-UU phenotype and paraoxonase (PON1) 55 M allele on the risk of systemic lupus erythematosus: influence on lipid and lipoprotein metabolism and oxidative stress, preliminary report.
    Bahrehmand F; Vaisi-Raygani A; Rahimi Z; Ahmadi R; Kiani A; Tavilani H; Vaisi-Raygani H; Pourmotabbed T
    Lupus; 2014 Mar; 23(3):263-72. PubMed ID: 24399815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paraoxonase 1 activities and genetic variation in childhood obesity.
    Rupérez AI; López-Guarnido O; Gil F; Olza J; Gil-Campos M; Leis R; Tojo R; Cañete R; Gil A; Aguilera CM
    Br J Nutr; 2013 Nov; 110(9):1639-47. PubMed ID: 23789921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paraoxonase 1 activity in patients with chronic obstructive pulmonary disease.
    Rumora L; Rajković MG; Kopčinović LM; Pancirov D; Čepelak I; Grubišić TŽ
    COPD; 2014 Sep; 11(5):539-45. PubMed ID: 24831724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of PON1 polymorphism on HDL antioxidant potential is blunted with aging.
    Cherki M; Berrougui H; Isabelle M; Cloutier M; Koumbadinga GA; Khalil A
    Exp Gerontol; 2007 Aug; 42(8):815-24. PubMed ID: 17532162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of plasma, erythrocytes, and bronchoalveolar lavage fluid antioxidant defense system in sulfur mustard-injured patients.
    Jafari M; Ghanei M
    Clin Toxicol (Phila); 2010 Mar; 48(3):184-92. PubMed ID: 20397800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between serum paraoxonase (PON1) gene promoter T(-107)C polymorphism, PON1 activity and HDL levels in healthy Sicilian octogenarians.
    Campo S; Sardo MA; Trimarchi G; Bonaiuto M; Fontana L; Castaldo M; Bonaiuto A; Saitta C; Bitto A; Manduca B; Riggio S; Saitta A
    Exp Gerontol; 2004 Jul; 39(7):1089-94. PubMed ID: 15236768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paraoxonase (PON1) polymorphism and activity as the determinants of sensitivity to organophosphates in human subjects.
    Sirivarasai J; Kaojarern S; Yoovathaworn K; Sura T
    Chem Biol Interact; 2007 Jul; 168(3):184-92. PubMed ID: 17532308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paraoxonase 1 gene polymorphisms and enzyme activities in coronary artery disease and its relationship to serum lipids and glycemia.
    Fridman O; Gariglio L; Riviere S; Porcile R; Fuchs A; Potenzoni M
    Arch Cardiol Mex; 2016; 86(4):350-357. PubMed ID: 27640339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of paraoxonase-192 polymorphism with low HDL-cholesterol in coronary artery disease risk.
    Mendonça MI; Dos Reis RP; Freitas AI; Pereira A; Sousa AC; Freitas S; Ornelas I; Freitas C; Brehm A; Araújo JJ
    Rev Port Cardiol; 2010 Apr; 29(4):571-80. PubMed ID: 20734577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antioxidant effect of atorvastatin is independent of PON1 gene T(-107)C, Q192R and L55M polymorphisms in hypercholesterolaemic patients.
    Sardo MA; Campo S; Bonaiuto M; Bonaiuto A; Saitta C; Trimarchi G; Castaldo M; Bitto A; Cinquegrani M; Saitta A
    Curr Med Res Opin; 2005 May; 21(5):777-84. PubMed ID: 15969877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulating effect of atorvastatin on paraoxonase 1 activity in type 2 diabetic Egyptian patients with or without nephropathy.
    Abdin AA; Hassanien MA; Ibrahim EA; El-Noeman Sel-D
    J Diabetes Complications; 2010; 24(5):325-33. PubMed ID: 19553142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abnormalities in the relationship of paraoxonase 1 with HDL and apolipoprotein A1 and their possible connection to HDL dysfunctionality in type 2 diabetes.
    Viktorinova A; Jurkovicova I; Fabryova L; Kinova S; Koren M; Stecova A; Svitekova K
    Diabetes Res Clin Pract; 2018 Jun; 140():174-182. PubMed ID: 29626583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Main determinants of PON1 activity in hemodialysis patients.
    Ribeiro S; do Sameiro Faria M; Mascarenhas-Melo F; Freitas I; Mendonça MI; Nascimento H; Rocha-Pereira P; Miranda V; Mendonça D; Quintanilha A; Belo L; Costa E; Reis F; Santos-Silva A
    Am J Nephrol; 2012; 36(4):317-23. PubMed ID: 23007074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paraoxonase 1 (PON1) organophosphate hydrolysis is not reduced in ALS.
    Wills AM; Landers JE; Zhang H; Richter RJ; Caraganis AJ; Cudkowicz ME; Furlong CE; Brown RH
    Neurology; 2008 Mar; 70(12):929-34. PubMed ID: 18347314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of protease inhibitors and an antioxidant for treatment of sulfur mustard-induced toxic lung injury.
    Anderson DR; Taylor SL; Fetterer DP; Holmes WW
    Toxicology; 2009 Sep; 263(1):41-6. PubMed ID: 18852015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.